TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · IEX Real-Time Price · USD
0.550
+0.028 (5.30%)
Apr 26, 2024, 4:00 PM EDT - Market closed

TransCode Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current20232022202120202019
Market Capitalization
43933--
Market Cap Growth
--62.08%-73.35%---
Enterprise Value
1141211
PE Ratio
-0.18-0.18-0.50-4.79--
PB Ratio
2.202.022.701.61--
P/FCF Ratio
-0.18-0.18-0.55-5.94--
P/OCF Ratio
-0.18-0.18-0.55-6.22--
EV/EBITDA Ratio
-0.06-0.06-0.22-1.78-0.65-1.61
EV/EBIT Ratio
-0.05-0.05-0.21-1.77-0.65-1.61
EV/FCF Ratio
-0.05-0.05-0.24-2.17-2.55-1.42
Debt / Equity Ratio
0.270.27---0.61-0.84
Debt / EBITDA Ratio
-0.03-0.03---1.07-2.06
Debt / FCF Ratio
-0.02-0.02---4.23-1.82
Quick Ratio
0.790.791.238.222.053.25
Current Ratio
1.281.281.708.972.053.25
Interest Coverage
-330.78-330.78-548.15-70.98-4.94-2.87
Return on Equity (ROE)
-934.70%-934.70%-171.70%-89.20%103.80%-
Return on Assets (ROA)
-276.10%-276.10%-133.60%-53.80%-372.10%-
Return on Capital (ROIC)
-928.50%-928.50%-574.99%-30.15%54.98%251.06%
Earnings Yield
-513.33%-559.95%-201.12%-20.88%--
FCF Yield
-501.27%-546.79%-181.64%-16.84%--
Buyback Yield / Dilution
-1003.48%-1003.48%-54.03%-81.74%--
Total Shareholder Return
-1003.48%-1003.48%-54.03%-81.74%--
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).